ClinicalTrials.gg
CompletedNCT06765070Updated Nov 16, 2026

Efficacy and Usability of the EXPLORER Exoskeleton in Children With Neurodevelopmental Disorders in Natural Environments

An interventional study of EXPLORER in Neuromuscular Disorders and Neurodevelopmental Disorders, sponsored by MarsiBionics. Completed at 6 sites in Spain. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by MarsiBionics · Not applicable, Interventional, and Treatment

How we know

Updated Nov 16, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Neuromuscular Diseases with a site in Spain — 5 open to participants now, 10 under way, 3 of them phase 3. Neuromuscular Diseases · Spain.

Enrollment
24th of 30
20 · median 55
Started
2025
with 5 others
No phase
14 of 35
2 open now
Registered
28th of 35
by date
Lead sponsor
6 of 35
MarsiBionics

Among the 35 studies in Neuromuscular Diseases with a site in Spain, this one is the 24th largest by enrollment of the 30 interventional ones that give a count, is one of 6 that started in 2025, is one of 14 with no phase, and was the 28th registered.

Neuromuscular Diseases

361 studies on the registry are indexed under Neuromuscular Diseases; 96 are open to participants now.

Browse Neuromuscular Diseases studies →

Open to participants now

5 of the 35 studies in Neuromuscular Diseases with a site in Spain are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 69 Neuromuscular Diseases studies recruiting now, 39 (57%) set no upper age limit and 22 (32%) stop at 75 or younger; 35 take children under 18; 16 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Neuromuscular Diseases with a site in Spain, or all of them as a file.
02

Study summary

Neurodevelopmental disorders often lead to abnormal development of the Central Nervous System (CNS), frequently causing motor dysfunctions such as an inability to stand and walk. EXPLORER is a robotic gait exoskeleton designed to rehabilitate children with motor disabilities in home and outdoor environments.

The aim of this study is to evaluate the efficacy and usability of EXPLORER in children with motor disability within their natural settings, including home and community environments.

Read the detailed description

Neurodevelopmental disorders often lead to abnormal development of the Central Nervous System (CNS), frequently causing motor dysfunctions such as an inability to stand and walk. Robotic devices are a useful tool in the rehabilitation of these children, but most of them are designed to be used in the clinical setting. EXPLORER is a robotic device designed to assist gait in children with motor disability in their homes and the community. The aim of this study is to evaluate the efficacy and usability of EXPLORER in children with motor disability within their natural settings, including home and community environments.

An initial session will be conducted in the participant's natural environment, during which the researchers will instruct the primary caregivers on the use of the device. Subsequently, the device will be left for a two-month period for use in the natural settings deemed appropriate by the family.

03

Conditions studied

  • Neuromuscular Disorders
  • Neurodevelopmental Disorders

Keywords

  • Neurodevelopmental disorders
  • Neuromuscular disorders
  • cerebral palsy
  • acquired brain injury
  • spinal muscular atrophy
  • robotics
  • gait
  • rehabilitation
  • spinal cord injury
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of any pathology or condition causing neurodevelopmental disorders.
  • Ability to continuously use the device for two weeks, at least 3 times per week, without causing excessive fatigue that would prevent the participant from carrying out their usual activities.
  • Availability and commitment from the family to use the device at least 3 times per week during the planned period, in different environments and with various objectives.
  • Medical authorization for standing, gait training and weight bearing.
  • signed by legal guardians.
  • Maximum user weight of 60 kg.
  • Hip width (between greater trochanters) ≤37 cm.
  • Length of the thigh (distance from the greater trochanter to the lateral condyle of the tibia) from 21cm to 36cm.
  • Tibia leg length (distance from the lateral condyle of the tibia to the lateral malleolus) from 20cm to 35cm.
  • Shoe size ≤40 (EU)

Exclusion criteria

Exclusion Criteria:

  • Medical for standing or walking.
  • Non-reducible contractures or heterotropic ossifications above the degrees allowed by the device or out of the trajectory imposed by the device
  • Spasticity equal to 4 on the Modified Ashworth Scale at the time of use of the device.
  • More than 20º of hip and/or knee non-reducible contractures at the time of using the exoskeleton.
  • Necessity to walk with more than 5º of hip abduction.
  • Impossibility to reach 5º of ankle dorsiflexion with ir without orthoses.
  • Lower length dysmetria that cannot be mitigated with a wedge under the foot.
  • Skin lesion on parts of the lower extremities that are in contact with the device.
  • History of fracture without trauma.
  • Presence of other conditions causing exercise intolerance (such as uncontrolled hypertension, coronary artery disease, arrhythmia, congestive heart failure, severe pulmonary disease).
  • Conductual disorders that may interfere with the use of the device or their participation in the study, like impulsiveness.
  • Allergy to any of the EXPLORER materials: cotton, nylon, polyester, PPS, PEEK or ABS.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    EXPLORER

    Two-week period with the robotics gait device for use in the natural settings deemed appropriate by the family.

    Device: EXPLORER

Interventions

  • DeviceEXPLORER

    Two-week period with the robotics gait device for use in the natural settings deemed appropriate by the family.

06

What researchers measure

Primary outcomes

  1. Serious Adverse Events

    occurrence of any serious adverse event to the participant or the caregiver

    Time frame: through study completion, along 2 weeks

  2. Falls prevalence

    Number of falling events occurred from the participant or caregiver

    Time frame: through study completion, along 2 weeks

  3. Skin integrity

    Occurrence of any injury of the skin in the areas of contact and produced by the use of the device

    Time frame: through study completion, along 2 weeks

  4. Pain (Visual Analogic Scale)

    pain measured by the Visual Analogic Scale (VAS) by the participant and the caregiver, scored from 0 to 10, being 0 "no pain" and 10 "unbearable pain"

    Time frame: through study completion, along 2 weeks

  5. Donning and doffing time

    Time to don and doff the device to each participant

    Time frame: through study completion, along 2 weeks

  6. Device usage time

    Time using the device

    Time frame: through study completion, along 2 weeks

  7. Number of steps

    number of steps with the device

    Time frame: through study completion, along 2 weeks

  8. Usage modes

    two different usage modes (active and automatic).

    Time frame: through study completion, along 2 weeks

  9. Speed

    speed achieved with the device (steps per minute)

    Time frame: through study completion, along 2 weeks

  10. Device accessibility

    Environments where the device has been used and level of accessibility in each environment measured with a 5 points Likert scale (0 not accessible - 5 very accessible)

    Time frame: through study completion, along 2 weeks

  11. Range of motion

    Passive Degree to which a joint can move (hip, knee, and ankle joints in both legs). From 0º to 180º.

    Time frame: Before starting the intervention (S1) and after completing the two weeks of use

  12. Participation

    Measured with the Child and Adolescent Scale of Participation. 20 ordinal scaled items across 4 subsections. Maximum total score is 80 (20 items x 4) and the minimum total score is 20 (20 items x 1)

    Time frame: Before starting the intervention (S1) and after completing the two weeks of use

Secondary outcomes

  1. QUEST

    Using the Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0) questionnaire administered to the participants' caregivers at the end of the intervention. The QUEST 2.0 scale has 12 items. Each item is rated on a 5-point Likert scale

    Time frame: at the end of the intervention

07

Study locations

6 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Aug 2026, 17 months.

Of 84 interventional studies with no phase under Neuromuscular Diseases, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's 17 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Apr 2025 → Aug 2026 and completion Dec 2025 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2024
First posted
Jan 9, 2025
StartActual
Mar 1, 2025
Primary completionActual
Aug 1, 2026was Apr 2025
CompletionActual
Sep 1, 2026was Dec 2025
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 16, 2026
Primary completion
Apr 1, 2025→Aug 1, 2026
Nov 16, 2026
Study completion
Dec 1, 2025→Sep 1, 2026 (actual)
Nov 16, 2026
Enrollment
15 (estimated)→20 (actual)
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Active, not recruiting→Completed
    Primary completion Apr 1, 2025→Aug 1, 2026
    Study completion Dec 1, 2025→Sep 1, 2026 (now actual)
    Enrollment 15 (estimated)→20 (actual)
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06765070
Lead sponsor
MarsiBionics
Collaborators
Hospital Infantil Universitario Niño Jesús, Madrid, Spain, Hospital General Universitario Gregorio Marañon, Hospital Universitario La Paz, Hospital Universitario 12 de Octubre, Universidad Rey Juan Carlos
Responsible party
Sponsor
First posted
Jan 9, 2025
Start date
Mar 1, 2025
Primary completion
Aug 1, 2026
Completion
Sep 1, 2026
Last update
Nov 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion